^
No biomarker
Fibrosarcoma
imatinib
Sensitive: A1 - Approval
No biomarker
Fibrosarcoma
pembrolizumab
Sensitive: A2 - Guideline
NTRK1 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
BRAF V600E
Neurofibrosarcoma
vemurafenib
Sensitive: C1 - Off-label
NTRK3 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
NF2 E108X
Neurofibrosarcoma
everolimus
Resistant: C3 – Early Trials
NF2 E108X
Neurofibrosarcoma
temsirolimus
Sensitive: C3 – Early Trials
TSC2 A736V
Neurofibrosarcoma
everolimus
Resistant: C3 – Early Trials
TSC2 A736V
Neurofibrosarcoma
temsirolimus
Sensitive: C3 – Early Trials
SQSTM1-NTRK1 fusion
Fibrosarcoma
VAC
Resistant: C4 – Case Studies
ETV6-NTRK3 fusion
Fibrosarcoma
VAC
Resistant: C4 – Case Studies
RBPMS-MET fusion
Fibrosarcoma
cabozantinib tablet
Sensitive: C4 – Case Studies
SQSTM1-NTRK1 fusion
Fibrosarcoma
doxorubicin hydrochloride + ifosfamide
Resistant: C4 – Case Studies
ETV6-NTRK3 fusion
Fibrosarcoma
larotrectinib
Sensitive: C4 – Case Studies
ETV6-NTRK3 fusion
Fibrosarcoma
vincristine + dactinomycin
Resistant: C4 – Case Studies
TMB-H + PD-L1 overexpression
Fibrosarcoma
cisplatin + ifosfamide + epirubicin
Resistant: C4 – Case Studies
TMB-H + PD-L1 overexpression
Fibrosarcoma
camrelizumab
Sensitive: C4 – Case Studies
TMB-H + PD-L1 overexpression
Fibrosarcoma
anlotinib
Resistant: C4 – Case Studies
TFG-ROS1 rearrangement
Fibrosarcoma
crizotinib
Sensitive: C4 – Case Studies
TJP1-ROS1 fusion + NF1 mutation
Neurofibrosarcoma
crizotinib
Resistant: C4 – Case Studies
ALK1 rearrangement
Fibrosarcoma
ceritinib
Resistant: C4 – Case Studies
ALK1 rearrangement
Fibrosarcoma
crizotinib
Resistant: C4 – Case Studies
CD8 positive
Fibrosarcoma
NKTR-214
Sensitive: D – Preclinical
CSPG4 overexpression
Fibrosarcoma
CSPG4.TNK
Sensitive: D – Preclinical
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
ceritinib + brentuximab vedotin
Sensitive: D – Preclinical
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
crizotinib + brentuximab vedotin
Sensitive: D – Preclinical
NF1 mutation
Neurofibrosarcoma
DR6MP + JHU395
Sensitive: D – Preclinical
NF1 mutation
Neurofibrosarcoma
DR6MP
Sensitive: D – Preclinical
NF1 mutation
Neurofibrosarcoma
MEK inhibitor + c-MET inhibitor
Sensitive: D – Preclinical